Effect of edaravone against cisplatin-induced chronic renal injury

References

• Chiazza, F., et al., 2015. A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia/reperfusion. Oxidative Medicine and Cellular Longevity, 2015, 804659.
   PubMed Web of Science ®Google Scholar
• de Jongh F.E., et al., 2003. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. British Journal of Cancer, 88 (8), 1199–1206.
   Google Scholar
• Dijkstra, G., Moshage, H., and Jansen, P.L., 2002. Blockade of NF-kappaB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease Scandinavian Journal of Gastroenterology Supplement, 37 (236), 37–41.
   Google Scholar
• Dobyan D.C., 1985. Long-term consequences of cis-platinum-induced renal injury: a structural and functional study. The Anatomical Record, 212 (3), 239–245.
   Google Scholar
• Dobyan, D. C., et al., 1981. Cyst formation in rat kidney induced by cis-platinum administration. Laboratory Investigation; a Journal of Technical Methods and Pathology, 45 (3), 260–268. 7196972
   PubMed Web of Science ®Google Scholar
• Emergency Safety Information About Radicut ® Injection [online], 2002. Pharmaceuticals and Medical Devices Agency. Available from: https://www.pmda.go.jp/files/000148149.pdf [Accessed 9 October 2018].
   Google Scholar
• Green, D.R., and Reed, J.C., 1998. Mitochondria and apoptosis. Science (New York, N.Y.), 281 (5381), 1309–1312.
   PubMed Web of Science ®Google Scholar
• Halestrap, A.P., Woodfield, K.Y., and Connern, C.P., 1997. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. The Journal of Biological Chemistry, 272 (6), 3346–3354.
   PubMed Web of Science ®Google Scholar
• Hisida, A., 2009. Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone. Clinical and Experimental Nephrology, 13, 118–122.
   PubMed Web of Science ®Google Scholar
• Iguchi, T., et al., 2004. Edaravone inhibits acute renal injury and cyst formation in cisplatin-treated rat kidney. Free Radical Research, 38 (4), 333–341.
   PubMed Web of Science ®Google Scholar
• Inoue, M., 2016. Regulation of oxidative stress and redox cycle in the kidney (in Japanese). Jinn to Touseki, 81 (6), 936–940.
   Google Scholar
• Jangra, A., et al., 2016. Edaravone alleviates cisplatin-induced neurobehavioral deficits via modulation of oxidative stress and inflammatory mediators in the rat hippocampus. European Journal of Pharmacology, 791, 51–61.
   PubMed Web of Science ®Google Scholar
• (JPIC) Japan Pharmaceutical Information Center., 2001. Nihonn no Shinnyaku -Shinnyaku Shouninn Shinnsa Houkokusho DB-. 'Edaravone Radicut Injection 30mg'. Japan Pharmaceutical Information Center. Available from: http://www.shinsahoukokusho.jp/dar_us/dar/search/usDarShowPDF.jsp?darId=191 [Accessed 9 October 2018].
   Google Scholar
• Kikuchi, K., et al., 2012. Beyond free radical scavenging: beneficial effects of edaravone (Radicut) in various diseases (Review). Experimental and Therapeutic Medicine, 3 (1), 3–8.
   PubMed Web of Science ®Google Scholar
• Komatsu, T., et al., 1996. Pharmacokinetic studies of 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186) in rats. (1). Blood and plasma levels, distribution, metabolism and excretion after a single intravenous administration (in Japanese). Yakubutsudoutai, 11 (5), 463–480.
   Google Scholar
• Kroemer, G., and Reed, J.C., 2000. Mitochondrial control of cell death. Nature Medicine, 6 (5), 513–519.
   PubMed Web of Science ®Google Scholar
• Li, Q., et al., 2016. Edaravone attenuates brain damage in rats after acute CO poisoning through inhibiting apoptosis and oxidative stress. Environmental Toxicology, 31 (3), 372–379.
   PubMed Web of Science ®Google Scholar
• Liu, X., et al., 1996. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell, 86 (1), 147–157.
   PubMed Web of Science ®Google Scholar
• Liu, L., et al., 2015. Protective effects of edaravone, a free radical scavenger, on lipopolysaccharide-induced acute kidney injury in a rat model of sepsis. International Urology and Nephrology, 47 (10), 1745–1752.
   PubMed Web of Science ®Google Scholar
• Liu, Z., et al., 2018. Neuroprotection of edaravone on the hippocampus of kainate-induced epilepsy rats through Nrf2/HO-1 pathway. Neurochemistry International, 112, 159–165.
   PubMed Web of Science ®Google Scholar
• Livak, K. J., and Schmittgen, T. D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San Diego, Calif.), 25 (4), 402–408. 11846609 10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Nakamura, T., 2013. Antibiotics -how to grasp the picture of drug-induced nephropathy (Koukinnyaku -Yakuzaisei-Jinnshougai no Toraekata). Gekkann Yakuji, 55 (13), 2367–2370.
   Google Scholar
• Nishikawa, M., et al., 2001. Targeting superoxide dismutase to renal proximal tubule cells inhibits mitochondrial injury and renal dysfunction inuduced by cisplatin. Archives of Biochemistry and Biophysics, 387 (1), 78–84.
   PubMed Web of Science ®Google Scholar
• Ohyama, N, et al., 2005. Influence of administration interval on rat renal injury in combination with cerebral protective drug edaravone and cephalothin/glycerol (nouhogoyaku edaravone to cefalotin/glycerol heiyouji no ratto jinnshougai ni oyobosu touyo kannkaku no eikyou). The 32nd Meeting of Japanese Toxicology Academic Society Annual Meeting, O–15.
   Google Scholar
• Safirstein, R., et al., 1986. Cisplatin nephrotoxicity. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 8 (5), 356–367.
   PubMed Web of Science ®Google Scholar
• Sasaki, A., et al., 2019. Dimetyl fumarate ameliorates cisplatin-induced renal tubulointerstitial lesions. Journal of Toxicologic Pathology, 32 (2), 79-89.
   Google Scholar
• Satoh, M., et al., 2003. A novel free radical scavenger, edarabone, protects against cisplatin-induced acute renal damage in vitro and in vivo. The Journal of Pharmacology and Experimental Therapeutics, 305 (3), 1183–1190.
   PubMed Web of Science ®Google Scholar
• Sattarinezhad, E., et al., 2017. Protective effect of edaravone against cyclosporine-induced chronic nephropathy through antioxidant and nitric oxide modulating pathways in rats. Iranian Journal of Medical Sciences, 42 (2), 170–178.
   PubMed Web of Science ®Google Scholar
• Sueishi, K., et al., 2002. Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats. European Journal of Pharmacology, 451 (2), 203–208.
   Google Scholar
• Suzuki, M., et al., 2000. The Combination of Fixation Using PLP Fixative and Embedding in Paraffin by the AMeX Method is Useful for Immunohistochemical and Enzyme Histochemical Studies of the Lung. Journal of Toxicologic Pathology, 13 (2), 109–113.
   Google Scholar
• Varatharajan, R., et al., 2016. Effect of edaravone in diabetes mellitus-induced nephropathy in rats. The Korean Journal of Physiology &Amp; Pharmacology: Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology, 20 (4), 333–340.
   PubMed Web of Science ®Google Scholar
• Watanabe, T., et al., 2004. Research and development of the free radical scavenger edaravone as a neuroprotectant. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 124 (3), 99–111.
   PubMed Web of Science ®Google Scholar
• Watanabe, K., et al., 2018. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? Journal of Clinical Biochemistry and Nutrition, 62 (1), 20–38.
   PubMed Web of Science ®Google Scholar
• Watanabe, T., et al., 1994. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. The Journal of Pharmacology and Experimental Therapeutics, 268 (3), 1597–1604.
   PubMed Web of Science ®Google Scholar
• Yokota, S., et al., 1997. A pharmacokinetic study of MCI-186, a novel drug for cerebrovascular disease in elderly and young healthy subjects (in Japanese). Japanese Journal of Clinical Pharmacology and Therapeutics, 28 (3), 693–702.
   Google Scholar
• Yonezawa, A., 2012. Platinum agent-induced nephrotoxicity via organic cation transport system. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 132 (11), 1281–1285.
   PubMed Web of Science ®Google Scholar
• Yonezawa, A., et al., 2005. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochemical Pharmacology, 70 (12), 1823–1831.
   PubMed Web of Science ®Google Scholar
• Zamami, Y., et al., 2016. Risk factor of acute renal failure induced by edaravone in patients with cerebrovascular disorder (in Japanese). Journal of Japanese Society for Emergency Medicine, 19, 461–465.
   Google Scholar
• Zhang, D., et al., 2018. Edaravone attenuates oxidative stress induced by chronic cerebral hypoperfusion injury: role of ERK/Nrf2/HO-1 signaling pathway. Neurological Research, 40 (1), 1–10.
   PubMed Web of Science ®Google Scholar